A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05675449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.
Study identification
- NCT ID
- NCT05675449
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2022 (Actual)
- Primary completion
- Mar 11, 2026 (Actual)
- Completion
- Feb 29, 2028 (Estimated)
- Last update posted
- Aug 13, 2026
2022 – 2028
United States locations
- U.S. sites
- 31
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| Clinical Research Advisors (Encino Satellite Location) | Encino | California | 91316 | — |
| Clinical Research Advisors (Korea Town Satellite Location) | Los Angeles | California | 90020 | — |
| Clinical Research Advisors (West Hollywood Satellite Location) | Los Angeles | California | 90048 | — |
| Sylvester Comprehensive Cancer Center - Aventura | Aventura | Florida | 33180 | — |
| Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center | Coral Gables | Florida | 33146 | — |
| Sylvester Comprehensive Cancer Center - Coral Springs | Coral Springs | Florida | 33065 | — |
| University of Miami Hospital and Clinics - Deerfield Beach | Deerfield Beach | Florida | 33442 | — |
| Sylvester Comprehensive Cancer Center - Hollywood | Hollywood | Florida | 33021 | — |
| Griffin Cancer Research Building (GCRB) | Miami | Florida | 33136 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | — |
| Sylvester Comprehensive Cancer Center - Kendall | Miami | Florida | 33176 | — |
| Sylvester Comprehensive Cancer Center - Plantation | Plantation | Florida | 33324 | — |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University Administration Office | Atlanta | Georgia | 30322 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| State University of Iowa, Division of Sponsored Programs | Iowa City | Iowa | 52242 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Oncology Investigational Drug Service,Department of Pharmacy Services | Baltimore | Maryland | 21231 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Johns Hopkins University Cancer Immunology/GI Oncology | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber/Mass General Brigham Cancer Care, Inc | Boston | Massachusetts | 02115 | — |
| MSK Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05675449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05675449 live on ClinicalTrials.gov.